Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
3
75%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
N/ANon-phased studies
3(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Completed2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A3 (100.0%)

Trials by Status

completed250%
recruiting250%

Recent Activity

2 active trials
Showing 4 of 4
recruiting

Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype

NCT06532734
recruitingnot_applicable

Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms

NCT06687603
completednot_applicable

CLUE: CLinical Utility Study of EsoGuard

NCT06030180
completednot_applicable

Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE

NCT04293458

Clinical Trials (4)

Showing 4 of 4 trials
NCT06532734

Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype

Recruiting
NCT06687603Not Applicable

Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms

Recruiting
NCT06030180Not Applicable

CLUE: CLinical Utility Study of EsoGuard

Completed
NCT04293458Not Applicable

Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE

Completed

All 4 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
4